Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients

SARICI A., ERKURT M. A., Bahcecioglu O. F., Gok S., KUKU İ., Bicim S., ...Daha Fazla

TRANSFUSION AND APHERESIS SCIENCE, cilt.60, sa.4, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.transci.2021.103159
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Anahtar Kelimeler: Chemomobilization, Cyclophosphamide, Filgrastim, Multiple myeloma, Autologous stem cell transplantation, STEM-CELL MOBILIZATION, COLONY-STIMULATING FACTOR, HIGH-DOSE CYCLOPHOSPHAMIDE, BLOOD PROGENITOR CELLS, LENALIDOMIDE THERAPY, INDUCTION THERAPY, TRANSPLANTATION, COLLECTION, IMPACT, CHEMOTHERAPY
  • İnönü Üniversitesi Adresli: Evet

Özet

Background and objective: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment approach in most multiple myeloma (MM) patients. Before ASCT, chemomobilization or only granulocyte-colony stimulating factor (G-CSF) mobilization can be preferred in stem cell mobilization. The primary aim of the study is to compare the effect of the two mobilization regimens on hematopoietic engraftment times, CD34+cell counts and number of apheresis required to harvest stem cells.